Most Read Articles
Dr Margaret Shi, 3 days ago

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Excerpts from the MY-COMPASSION Expert Meeting

30 Jan 2019
BTcP is defined as: “A transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain”.1,2 While there are various pain profiles associated with BTcP, a BTcP episode is typically severe, reaching peak pain intensity within 1–3 minutes from onset and is short in duration (ie, subsiding within 30 minutes).In Malaysia, opioids such as oral immediate-release(IR), intravenous (IV) and subcutaneous (SC) morphine are prescribed as ‘rescue’ medications for BTcP.2 IR opioids reach peak concentrations around 1 hour post-administration,and have a half-life of 3–6 hours, which may be suitable for longer duration BTcP episodes, but may not sufficiently address ‘sharp’, short-duration BTcP.2 In contrast, the faster onset of action seen in ROOs (eg, SLF which reaches peak plasma concentrations within 30–60 minutes post-administration) may be better suited for such episodes of BTcP.3,4

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 3 days ago

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.